Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

Long-Suffering Rohingya In Bangladesh Face Unacceptable Abuse
Thousands of unregistered Rohingya refugees living in the Kutupalong makeshift camp, Bangladesh, are being forcibly displaced from their homes, in an act of intimidation and abuse by the local authorities. The international medical organization Doctors Without Border/Mç©decins Sans Frontiç¨res (MSF) has treated numerous people for injuries, of which the majority were women and children. Furthermore, MSF has witnessed countless destroyed homes and heard many reports of people being warned to remove their own shelters or face the consequences.
generic viagra online
Bring On The "Suds": Prototype, 7-Foot-Tall Sanitizer Automates Disinfection Of Hard-to-Clean Hospital Equipment
Johns Hopkins experts in applied physics, computer engineering, infectious diseases, emergency medicine, microbiology, pathology and surgery have unveiled a 7-foot-tall, $10,000 shower-cubicle-shaped device that automatically sanitizes in 30 minutes all sorts of hard-to-clean equipment in the highly trafficked hospital emergency department. The novel device can sanitize and disinfect equipment of all shapes and sizes, from intravenous line poles and blood pressure cuffs, to pulse oximeter wires and electrocardiogram (EKG) wires, to computer keyboards and cellphones.
News of the day
The Importance Of Medicaid Continuity For Former Inmates
It is time for states to suspend, rather than terminate, the Medicaid benefits of inmates while they are incarcerated, say correctional health care experts from The Miriam Hospital in a commentary published online by the Journal of General Internal Medicine.
Medical Devices

WHO, Wyeth Launch Trial In Africa To Test New River Blindness Drug

The WHO on Wednesday announced plans for a clinical trial to test a new drug that "could halve the treatment period for river blindness [or onchocerciasis], a disease that threatens 100 million people mostly in Africa," AFP/Dow Jones Newswires/CNN Money reports (7/1). "This is a devastating illness that has plagued 30 African countries for centuries, in particular the populations in the most remote areas "beyond the end of the road,"" Uche Amazigo, director of the African Programme for Onchocerciasis Control (APOC), said (ANI/Thaindian.com, 7/1). According to the WHO, fifteen hundred people from four sites in Ghana, Liberia and Congo will participate in the phase three trial to measure the effectiveness of the drug moxidectin over the next two and a half years, SciDev.net reports. River blindness is caused by the parasitic worm whose larvae are transmitted from person to person by blackflies. SciDev.net writes, "Adult worms can live in the body for up to 15 years, producing millions of larval worms that migrate through the skin and eyes - causing blindness" (Aguilar, 7/1). "Moxidectin, now used to treat parasites in dogs, cats, horses and cattle, shows potential to destroy the worms that cause river blindness," Reuters reports. The pharmaceutical company Wyeth has reformulated the drug for human use (MacInnis, 7/1). "Since moxidectin kills not only the larvae but also sterilizes or kills the adult worms, it has the potential to interrupt the disease transmission cycle within around six annual rounds of treatment," the WHO said in a written statement. This would be an improvement over the current drug used to fight river blindness, ivermectin, which is able to kills the parasitic worm larvae but not adult worms, requiring annual treatments for more than a decade for control of the disease (7/1). In collaboration with Wyeth, the WHO Special Programme for Research and Training in Tropical Diseases (WHO/TDR) will run the clinical trials. "WHO/TDR has been working with African investigators and institutions in the three countries since 2007 to ensure existing or new centres are capable of conducting the trials, and the hope is that this capacity building will enable further trials," SciDev.Net writes (7/1). This information was reprinted from globalhealth.kff.org with kind permission from the Henry J. Kaiser Family Foundation. You can view the entire Kaiser Daily Global Health Policy Report, search the archives and sign up for email delivery at globalhealth.kff.org. © Henry J. Kaiser Family Foundation. All rights reserved.


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009